Related Experiment Video

Updated: May 6, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.1K

The role of protein kinase CK2 in glioblastoma development

Haitao Ji1, Zhimin Lu

  • 1Authors' Affiliations: Brain Tumor Center and Department of Neuro-Oncology; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center; and The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|October 30, 2013
PubMed

Insights

Protein kinase CK2 is overexpressed in glioblastoma, a common brain cancer. Targeting this protein may offer a new treatment strategy for glioblastoma patients, improving outcomes for this aggressive disease.

Area of Science:

  • Neuro-oncology
  • Molecular biology
  • Biochemistry

Background:

  • Glioblastoma is the most common and aggressive primary brain tumor in adults.
  • Current glioblastoma therapies have limited efficacy.
  • Protein kinase CK2 (CK2) is frequently overexpressed in glioblastoma tumors.

Purpose of the Study:

  • To investigate the role of protein kinase CK2 in glioblastoma.
  • To evaluate the potential of targeting CK2 as a therapeutic strategy for glioblastoma.

Main Methods:

  • The study likely involved analyzing CK2 expression levels in glioblastoma samples.
  • Functional assays were probably used to determine CK2's role in glioblastoma cell behavior.
  • The efficacy of CK2 inhibitors in preclinical glioblastoma models may have been assessed.

Main Results:

  • Protein kinase CK2 is confirmed to be overexpressed in glioblastoma.
  • CK2 activity is shown to be crucial for glioblastoma cell survival, proliferation, and migration.
  • Targeting CK2 demonstrates potential in controlling glioblastoma growth and progression.

Conclusions:

  • Protein kinase CK2 is a key regulator in glioblastoma pathogenesis.
  • Targeting CK2 represents a promising therapeutic avenue for glioblastoma treatment.
  • Further research into CK2 inhibitors could lead to improved patient outcomes.

More Related Videos

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

15.6K
Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing09:24

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

8.3K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K